PodParley PodParley
PodParley
Ep. 45 Urothelial Carcinoma: Understanding ctDNA & Precision Medicine with Dr. Amanda Nizam and Dr. Brad McGregor episode artwork

EPISODE · Jan 27, 2026 · 59 MIN

Ep. 45 Urothelial Carcinoma: Understanding ctDNA & Precision Medicine with Dr. Amanda Nizam and Dr. Brad McGregor

from BackTable Tumor Board · host BackTable Inc.

Is the era of cisplatin over, or are we simply becoming more precise about who benefits from it? As perioperative strategies in bladder cancer continue to evolve, emerging tools like circulating tumor DNA (ctDNA) are playing a bigger role in how clinicians assess recurrence risk and tailor treatment. In this episode of BackTable Tumor Board, host Alan Tan, medical oncologist at Vanderbilt-Ingram Cancer Center, is joined by bladder cancer experts Dr. Amanda Nizam and Dr. Brad McGregor to discuss recent advances in the diagnosis and treatment of urothelial carcinoma. --- SYNPOSIS The doctors examine the evolving management of muscle-invasive bladder cancer (MIBC), including the role of neoadjuvant and adjuvant therapies, the integration of immunotherapy, and the recent approval of enfortumab vedotin plus pembrolizumab. The discussion explores the rapidly changing perioperative landscape, the prognostic utility of ctDNA, and how biomarkers such as HER2 and FGFR are influencing treatment selection across disease states. They also address bladder preservation strategies, management of treatment-related toxicities, and the importance of multidisciplinary coordination. The episode concludes with a forward-looking discussion on emerging therapies and the potential to improve cure rates in bladder cancer. --- TIMESTAMPS 00:00 - Introduction01:44 - Overview of Bladder Cancer Treatment04:54 - Patient Staging and Treatment Goals10:12 - Bladder Preservation vs. Radical Cystectomy16:39 - Emerging Trials and Future Directions22:40 - ctDNA and Precision Medicine33:50 - Metastatic Disease and Biomarker Strategies42:16 - Managing Neuropathy in Metastatic Treatment48:44 - HER2 and FGFR in Bladder Cancer54:15 - Future Directions in Bladder Cancer Treatment --- RESOURCES EV-302/303 Trialhttps://newsroom.astellas.com/2023-12-15-PADCEV-R-enfortumab-vedotin-ejfv-with-KEYTRUDA-R-pembrolizumab-Approved-by-FDA-as-the-First-and-Only-ADC-Plus-PD-1-to-Treat-Advanced-Bladder-Cancer NIAGARA Regimenhttps://www.nejm.org/doi/full/10.1056/NEJMoa2408154 KEYNOTE-905 Studyhttps://www.annalsofoncology.org/article/S0923-7534(25)04894-X/fulltext

What this episode covers

Is the era of cisplatin over, or are we simply becoming more precise about who benefits from it? As perioperative strategies in bladder cancer continue to evolve, emerging tools like circulating tumor DNA (ctDNA) are playing a bigger role in how clinicians assess recurrence risk and tailor treatment. In this episode of BackTable Tumor Board, host Alan Tan, medical oncologist at Vanderbilt-Ingram Cancer Center, is joined by bladder cancer experts Dr. Amanda Nizam and Dr. Brad McGregor to discuss recent advances in the diagnosis and treatment of urothelial carcinoma. --- SYNPOSIS The doctors examine the evolving management of muscle-invasive bladder cancer (MIBC), including the role of neoadjuvant and adjuvant therapies, the integration of immunotherapy, and the recent approval of enfortumab vedotin plus pembrolizumab. The discussion explores the rapidly changing perioperative landscape, the prognostic utility of ctDNA, and how biomarkers such as HER2 and FGFR are influencing treatment selection across disease states. They also address bladder preservation strategies, management of treatment-related toxicities, and the importance of multidisciplinary coordination. The episode concludes with a forward-looking discussion on emerging therapies and the potential to improve cure rates in bladder cancer. --- TIMESTAMPS 00:00 - Introduction01:44 - Overview of Bladder Cancer Treatment04:54 - Patient Staging and Treatment Goals10:12 - Bladder Preservation vs. Radical Cystectomy16:39 - Emerging Trials and Future Directions22:40 - ctDNA and Precision Medicine33:50 - Metastatic Disease and Biomarker Strategies42:16 - Managing Neuropathy in Metastatic Treatment48:44 - HER2 and FGFR in Bladder Cancer54:15 - Future Directions in Bladder Cancer Treatment --- RESOURCES EV-302/303 Trialhttps://newsroom.astellas.com/2023-12-15-PADCEV-R-enfortumab-vedotin-ejfv-with-KEYTRUDA-R-pembrolizumab-Approved-by-FDA-as-the-First-and-Only-ADC-Plus-PD-1-to-Treat-Advanced-Bladder-Cancer NIAGARA Regimenhttps://www.nejm.org/doi/full/10.1056/NEJMoa2408154 KEYNOTE-905 Studyhttps://www.annalsofoncology.org/article/S0923-7534(25)04894-X/fulltext

NOW PLAYING

Ep. 45 Urothelial Carcinoma: Understanding ctDNA & Precision Medicine with Dr. Amanda Nizam and Dr. Brad McGregor

0:00 59:18

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

API Intersection Stoplight Building a successful API requires more than just coding. It starts with collaborative design, focuses on creating a great developer experience, and ends with getting your company on board, maintaining consistency, and maximizing your API’s profitability.In the API Intersection, you’ll learn from experienced API practitioners who transformed their organizations, and get tangible advice to build quality APIs with collaborative API-first design.Jason Harmon brings over a decade of industry-recognized REST API experience to discuss topics around API design, governance, identity/auth versioning, and more.They’ll answer listener questions, and discuss best practices on API design (definition, modeling, grammar), Governance (multi-team design, reviewing new API’s), Platform Transformation (culture, internal education, versioning) and more.They’ll also chat with experienced API practitioners from a wide array of industries to draw out practical takeaways and insights you can use.H PDF feed of Interpreter: A Journal of Latter-day Saint Faith and Scholarship PDF feed of Interpreter: A Journal of Latter-day Saint Faith and Scholarship The Interpreter Foundation is a nonprofit educational organization focused on the scriptures of The Church of Jesus Christ of Latter-day Saints (the Book of Mormon, the Pearl of Great Price, the Bible, and the Doctrine and Covenants), early LDS history, and related subjects. All publications in its journal, Interpreter: A Journal of Latter-day Saint Faith and Scholarship, are peer-reviewed and made available as free internet downloads or through at-cost print-on-demand services. Other posts on the website are not necessarily peer-reviewed, but are approved by Interpreter’s Executive Board.Our goal is to increase understanding of scripture through careful scholarly investigation and analysis of the insights provided by a wide range of ancillary disciplines, including language, history, archaeology, literature, culture, ethnohistory, art, geography, law, politics, philosophy, statistics, etc. Interpreter will also publish articles advocating the authenticity and historicity Passive Investing Podcast The Real Estate Women The Passive Investing Podcast is a round table discussion where we teach you how to create a stream of passive income through Multi Family investing. Crystal, Candy, Colleen & Tamara dive into the classroom, board room and living room on Multi Family real estate investing, with Guests Matt Pichney, Rod Khleif, and Julie Holly pulling up a chair to share stories and insight on their areas of expertise. Whether you’re trying to jump into real estate to free yourself from the grind of the 9-5, to build a stream of passive income or to create generational wealth, join us at the table! Brasher Warning Brasher Warning Brasher Warning: Exploring the Skies, One Close Call at a Time: Take a deep dive into the intense world of aviation incidents with Brasher Warning, a podcast that explores the stories behind near misses, full-blown accidents, and everything in between. As a busy Chicago-based air traffic controller, husband, and father of two amazing girls, my time is limited, but my passion for aviation safety has never wavered. Thanks to cutting-edge AI, I’ve discovered a way to bring this passion back into my life—and now, into yours. Each episode unpacks real-life aviation events using detailed reports, including those from the National Transportation Safety Board (NTSB), weaving them into seamless, digestible narratives. Whether on my way to work, during a quick break, or while I’m getting ready for the day, AI allows me to analyze mountains of data and transform it into compelling stories that inform and entertain. And now I’m sharing that with you. Whether you’re an aviation enthusiast, a cur

Frequently Asked Questions

How long is this episode of BackTable Tumor Board?

This episode is 59 minutes long.

When was this BackTable Tumor Board episode published?

This episode was published on January 27, 2026.

What is this episode about?

Is the era of cisplatin over, or are we simply becoming more precise about who benefits from it? As perioperative strategies in bladder cancer continue to evolve, emerging tools like circulating tumor DNA (ctDNA) are playing a bigger role in how...

Can I download this BackTable Tumor Board episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!